Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-11-2021 | Cystic Fibrosis | Brief Report

Fatal Pandoraea nosoerga infection after combined liver-lung transplantation for cystic fibrosis: a recontamination by the pre-transplantation strain

Authors: Lucie Peyclit, Sophie Alexandra Baron, Martine Reynaud-Gaubert, Nadim Cassir, Jean-Marc Rolain

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2021

Abstract

A 26-year-old girl with a longstanding colonization by Pandoraea nosoerga underwent liver-lung transplantation for cystic fibrosis (CF) in 2018. Her brother also suffering from CF was also colonized by P. nosoerga. Despite appropriate perioperative antibiotic therapy, she had post-transplant bacteremic pneumonia caused by extensively drug-resistant P. nosoerga. Drug repurposing was used to optimize treatment options. The cause of post-transplant contamination was studied by comparative whole-genome sequencing including pre- and post-transplant strains and her brother’s strains. Post-transplant contamination appeared to be due to her own pre-transplant strain, emphasizing the urgent need to study and implement effective decontamination protocols before transplantation.

Available only for authorised users

Green H, Jones AM (2015) The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med 36:225–235. https://doi.org/10.1055/s-0035-1546752CrossRefPubMed

Snell G, Reed A, Stern M, Hadjiliadis D (2017) The evolution of lung transplantation for cystic fibrosis: a 2017 update. J Cyst Fibros 16:553–564. https://doi.org/10.1016/j.jcf.2017.06.008CrossRefPubMed

Dupont L (2017) Lung transplantation in cystic fibrosis patients with difficult to treat lung infections. Curr Opin Pulm Med 23:574–579. https://doi.org/10.1097/MCP.0000000000000431CrossRefPubMed

Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA et al (2007) Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Hear Lung Transplant 26:834–838. https://doi.org/10.1016/j.healun.2007.05.018CrossRef

Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T et al (2001) Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 163:43–48. https://doi.org/10.1164/ajrccm.163.1.9811076CrossRefPubMed

Nosotti M, Tarsia P, Corinna ML (2018) Infections after lung transplantation. J Thorac Dis 10:3849–3868. https://doi.org/10.21037/jtd.2018.05.204CrossRefPubMedPubMedCentral

Coiffard B, Prud’Homme E, Hraiech S, Cassir N, Le Pavec J, Kessler R et al (2020) Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation. BMC Pulm Med 20:109. https://doi.org/10.1186/s12890-020-1151-9CrossRefPubMedPubMedCentral

Rhodes KA, Schweizer HP (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82–90. https://doi.org/10.1016/j.drup.2016.07.003CrossRefPubMedPubMedCentral

Zhang T, Price MB, Bravo N, Villarreal JA, Kueht ML, Vierling JM et al (2020) Combined lung-liver and delayed kidney transplantation for cystic fibrosis clinical approach and outcome: a case report. Transplant Proc 52:2824–2826. https://doi.org/10.1016/j.transproceed.2020.02.154CrossRefPubMed

10.

Hadjadj L, Baron SA, Diene SM, Rolain JM (2019) How to discover new antibiotic resistance genes? Expert Rev Mol Diagn 19:349–362. https://doi.org/10.1080/14737159.2019.1592678CrossRefPubMed

11.

Peeters C, De Canck E, Cnockaert M, De Brandt E, Snauwaert C, Verheyde B et al (2019) Comparative genomics of Pandoraea, a genus enriched in xenobiotic biodegradation and metabolism. Front Microbiol 10:2556. https://doi.org/10.3389/fmicb.2019.02556CrossRefPubMedPubMedCentral

12.

Peyclit L, Baron SA, Rolain J-M (2019) Drug repurposing to fight colistin and carbapenem-resistant bacteria. Front Cell Infect Microbiol 9:193. https://doi.org/10.3389/fcimb.2019.00193CrossRefPubMedPubMedCentral

13.

Bayjanov JR, Ekkelenkamp MB, Rogers MR, Cantón R, Benaissa-Trouw BJ, Díez-Aguilar M et al (2019) Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients. Future Microbiol 14:1357–1367. https://doi.org/10.2217/fmb-2019-0038CrossRefPubMed

14.

Shah A, Pasrija C, Boulos F, Pham S, Griffith BP, Amoroso A et al (2019) Decontamination and lung transplantation of a patient with cystic fibrosis with resistant infections. Ann Thorac Surg 107:e239–e241. https://doi.org/10.1016/j.athoracsur.2018.08.058CrossRefPubMed

15.

Dupont C, Aujoulat F, Chiron R, Condom P, Jumas-Bilak E, Marchandin H (2017) Highly diversified Pandoraea pulmonicola population during chronic colonization in cystic fibrosis. Front Microbiol 8:1892. https://doi.org/10.3389/fmicb.2017.01892CrossRefPubMedPubMedCentral

16.

Rolain JM, Baquero F (2016) The refusal of the Society to accept antibiotic toxicity: missing opportunities for therapy of severe infections. Clin Microbiol Infect 22:423–427. https://doi.org/10.1016/j.cmi.2016.03.026CrossRefPubMed

Title: Fatal Pandoraea nosoerga infection after combined liver-lung transplantation for cystic fibrosis: a recontamination by the pre-transplantation strain
Authors: Lucie Peyclit
Sophie Alexandra Baron
Martine Reynaud-Gaubert
Nadim Cassir
Jean-Marc Rolain
Publication date: 01-11-2021
Publisher: Springer Berlin Heidelberg
Keywords: Cystic Fibrosis
Antibiotic
Cystic Fibrosis
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04235-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fatal Pandoraea nosoerga infection after combined liver-lung transplantation for cystic fibrosis: a recontamination by the pre-transplantation strain

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2021

Accuracy of saliva and nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric cohort study

Bartonella infections diagnosed in the French reference center, 2014–2019, and focus on infections in the immunocompromised

Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France

Combined selective culture and molecular methods for the detection of carbapenem-resistant organisms from fecal specimens

Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page